Cingulate Inc. (CING)
Cingulate Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Kansas City, KS, US. The stock last traded at $5.07, down 2.50% on the session, giving a market capitalisation of $68.3M. On trailing twelve-month figures it carries a trailing P/E of -1.01, a net margin of 0.0%. Its beta of -0.91 implies it has historically moved less than the broad market.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Cingulate Inc. is most often compared with the following Healthcare names: